New eye drops aim to tame blinding disease – first safety test in humans
Disease control
Completed
This early-stage study tested the safety of SCAI-005 eye drops in 48 healthy Korean adults aged 19 to 50. The drops contain axitinib, a drug that may help control wet age-related macular degeneration, a leading cause of vision loss. Researchers monitored side effects and how the …
Phase: PHASE1 • Sponsor: SCAI Therapeutics • Aim: Disease control
Last updated May 17, 2026 10:28 UTC